Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials

The marine environment has proven to be a very rich source of extremely potent compounds that have demonstrated significant activities in antitumor, antiinflammatory, analgesia, immunomodulation, allergy, and anti-viral assays. Although the case can and has been made that the nucleosides such as Ara...

Full description

Saved in:
Bibliographic Details
Published in:Journal of natural products (Washington, D.C.) D.C.), 2004-08, Vol.67 (8), p.1216-1238
Main Authors: Newman, David J, Cragg, Gordon M
Format: Article
Language:English
Subjects:
Animals
Antineoplastic agents
Biological and medical sciences
Biological Products
Bones, joints and connective tissue. Antiinflammatory agents
Brackish
Clinical Trials as Topic
Drug Evaluation, Preclinical
General aspects
General pharmacology
Immunomodulators
Marine
Marine Biology
Medical sciences
Molecular Structure
Pharmacognosy. Homeopathy. Health food
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The marine environment has proven to be a very rich source of extremely potent compounds that have demonstrated significant activities in antitumor, antiinflammatory, analgesia, immunomodulation, allergy, and anti-viral assays. Although the case can and has been made that the nucleosides such as Ara-A and Ara-C are derived from knowledge gained from investigations of bioactive marine nucleosides, no drug directly from marine sources (whether isolated or by total synthesis) has yet made it to the commercial sector in any disease. However, as shown in this review, there are now significant numbers of very interesting molecules that have come from marine sources, or have been synthesized as a result of knowledge gained from a prototypical compound, that are either in or approaching Phase II/III clinical trials in cancer, analgesia, allergy, and cognitive diseases. A substantial number of other potential agents are following in their wake in preclinical trials in these and in other diseases.
ISSN:0163-3864
1520-6025
DOI:10.1021/np040031y